138 related articles for article (PubMed ID: 7981447)
1. Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study.
Bhatavdekar JM; Patel DD; Karelia NH; Vora HH; Ghosh N; Shah NG; Balar DB; Trivedi SN
Breast Cancer Res Treat; 1994; 30(3):293-7. PubMed ID: 7981447
[TBL] [Abstract][Full Text] [Related]
2. Circulating markers and growth factors as prognosticators in men with advanced tongue cancer.
Bhatavdekar JM; Patel DD; Vora HH; Balar DB
Tumour Biol; 1993; 14(1):55-8. PubMed ID: 8493451
[TBL] [Abstract][Full Text] [Related]
3. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.
Uehara M; Kinoshita T; Hojo T; Akashi-Tanaka S; Iwamoto E; Fukutomi T
Int J Clin Oncol; 2008 Oct; 13(5):447-51. PubMed ID: 18946756
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
7. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
[TBL] [Abstract][Full Text] [Related]
8. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
9. [CA 15-3 and CEA markers - prognostic factors in breast cancer].
Anton E; Costăchescu G; Costăchescu G
Rev Med Chir Soc Med Nat Iasi; 2001; 105(1):161-4. PubMed ID: 12092146
[TBL] [Abstract][Full Text] [Related]
10. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
15. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
16. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
17. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
[TBL] [Abstract][Full Text] [Related]
18. Elevated CA125 in breast cancer--A sign of advanced disease.
Norum LF; Erikstein B; Nustad K
Tumour Biol; 2001; 22(4):223-8. PubMed ID: 11399947
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer.
Kumpulainen EJ; Keskikuru RJ; Johansson RT
Breast Cancer Res Treat; 2002 Nov; 76(2):95-102. PubMed ID: 12452445
[TBL] [Abstract][Full Text] [Related]
20. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
